Joannes A. A. Reijers

A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease

David Kallend, Joannes A. A. Reijers, S. Eralp Bellibas et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2015 · 75 citations · Full text

Evidence of NI‐0101 pharmacological activity, an anti‐TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

Emmanuel Monnet, G Lapeyre, Eveline P. van Poelgeest et al. · Clinical Pharmacology & Therapeutics · 2016 · 75 citations

MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216

Joannes A. A. Reijers, David Kallend, Karen E. Malone et al. · Cardiovascular Drugs and Therapy · 2017 · 48 citations · Full text

A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers

Liselijn A. B. Wisman, Eduard P. M. De Cock, Joannes A. A. Reijers et al. · Clinical Drug Investigation · 2014 · 32 citations

Bioequivalence Study, Medicine, Healthy Male Volunteers +3

Safety and dose‐dependency of eptacog beta (activated) in a dose escalation study of non‐bleeding congenital haemophilia A or B patients, with or without inhibitors

Jonathan M. Ducore, Jeanne B. Lawrence, Mindy Simpson et al. · Haemophilia · 2017 · 18 citations · Full text